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Abstract
Background There has been an extensive range of incidence and mortality of breast cancer (BC), and the comprehensively 
available treatments for BC have not been completely successful in achieving satisfactory outcomes up to date.
Hypothesis Recently, we are watching intense attention paid to the utilization of natural compounds as a novel therapeutic 
strategy for cancer treatment. Quercetin, a dietary flavonol in a large group of commonly consumed foods, is widely illustrated 
to apply inhibitory effects on cancer progression through several mechanisms including apoptosis enhancement, cell cycle 
arrest, metastasis and angiogenesis inhibition, antioxidant replication and estrogen receptor modulation.
Methods We reviewed the most relevant papers published from 2009 to 2018 (except 15 articles), using “pub med” and “web 
of science” and the search terms “Quercetin”; “Breast cancer”; “Flavonoid”; “Apoptosis”; “Cell cycle”; “chemotherapy”; 
“Drug resistance”; “Metastasis; “Oxidative stress”, “Breast cancer receptors” and “Quercetin derivatives”. We selected 
studies on the association of quercetin with breast cancer in different dimensions.
Results Despite the remarkable number of studies on quercetin’s efficacy, multiple aspects of this herbal compound have 
not been clarified well and this review provides a summarized update of the recent evidence on biologically available effica-
cies of quercetin which would establish a further biological basis for the potential therapeutic acquisition of quercetin as an 
anticancer drug.
Conclusion Basic, epidemiological and genetic studies point to the potential role of quercetin in the treatment of breast 
cancer, but randomized and controlled trials are of great importance to establish the clinical efficacy of quercetin in ill or 
at-risk subjects.
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Abbreviations
ABC  ATP-binding cassette 
transporters
AKT  AK strain transforming also 
known as protein kinase B 
(PKB): a serine/threonine-spe-
cific protein kinase
AP-1  Activator protein 1: a transcrip-
tion factor regulating gene 
expression
Apaf-1  Apoptotic protease activating 
factor 1: a cytoplasmic protein 
that forms one of the central 
hubs in the apoptosis regulatory 
network
Apo3  Ligand of death receptor
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BCL-2  B-cell lymphoma 2: a founding 
member of the Bcl-2 family, 
regulating apoptosis
c-FLIP  Caspase FLICE-like inhibitory 
protein: preventing DISC forma-
tion by binding to FADD and/
or caspase-8 or -10 and TRAIL 
receptor 5 (DR5)
DR  Death receptor: transmembrane 
proteins controlling the extrinsic 
pathway
FADD  Fas-associated protein with 
death domain: an adaptor pro-
tein bridging member of TNFR 
superfamily
GADD45  Growth arrest and DNA dam-
age: stress sensors modulating 
the response of mammalian cells 
to stress and tumor formation
GSH  Glutathione peroxidase: a trip-
eptide that act as an antioxidant 
and preventing cells of damage 
by reactive oxygen species
Hif-1α  Hypoxia-inducible factor 1: 
subunit of hif transcription fac-
tor that is regulator of cellular 
and developmental response to 
hypoxia
m-TOR  The mammalian target of rapa-
mycin, also known as FK506-
binding protein 12-rapamycin-
associated protein 1 (FRAP1): 
a kinase that regulates different 
cellular process
MAPK  A mitogen-activated protein 
kinase: a type of protein kinase 
that activates transcription fac-
tors such as AP-1 in cells
NFAT  Nuclear factor of activated 
T-cells: a family of transcription 
factors shown to be important in 
immune response. One or more 
members of the NFAT family 
are expressed in most cells of 
the immune system
Nrf-2  The nuclear factor erythroid 
2-related factor 2 (Nrf2): an 
emerging regulator of cellular 
resistance to oxidants which 
controls the expression of anti-
oxidant response
PI3K  Phosphatidyl inositol 3-kinase: 
a family of intracellular signal 
inducer enzymes involved in 
cellular functions such as cell 
growth, proliferation, differen-
tiation and survival
Pin-1  Peptidyl-prolyl cis–trans 
Isomerase NIMA-interacting 1: 
an enzyme that deregulation of 
this enzyme plays a role in dif-
ferent diseases
PKM2  Pyruvate kinase isozyme M2 
(PKM2) is metabolic-related 
enzymes expressed in different 
tissues
ROS  Reactive oxygen spices: formed 
as a natural byproduct of the 
normal metabolism of oxygen 
that includes peroxides, super-
oxide and hydroxyl radical
SOD  Superoxide dismutase: an 
important enzyme that helps in 
protecting against the damage of 
ROS
TNF  Tumor necrosis factor: a cell 
signaling protein involved in 
systemic inflammation and acute 
phase reactions
TRAIL  TNF-related apoptosis-inducing 
ligand: a protein functioning as 
a ligand that induces apoptosis
VEGF  Vascular endothelial growth fac-
tor: a signal protein that stimu-
lates the formation of blood 
vessels
MCF-7 cell line  Michigan cancer foundation-7: 
estrogen, progesterone recep-
tors positive, HER2 negative 
and perfect model for hormone 
therapy
MDA-MB-231 cell line  M.D. Anderson-Metastasis 
Breast cancer-231: triple nega-
tive cell line (ER, PR and HER2 
Negative) and shows intermedi-
ate response to chemotherapy
MDA-MB-468 cell line  M.D. Anderson-Metastasis 
Breast cancer-468: triple-nega-
tive cell line (ER, PR and HER2 
negative) and often chemother-
apy responsive
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Introduction
Breast cancer (BC), defining by breast tissue originated 
cancer, occupies the second leading cause of non-skin can-
cers (inferior to lung cancer), the most common cause of 
cancer death among women worldwide (Lauby-Secretan 
et al. 2015), and one of the three most frequently diag-
nosed cancers in women worldwide (Tinoco et al. 2013; 
Torre et al. 2017), which has comprised around 7–10% 
of all malignant tumors, globally (Chow and Loo 2003).
BC has various incidences of 1–2% and nearly 5% 
yearly increase in developed countries and less developed 
countries, respectively. Based on statistics received from 
World Health Organization (WHO), there have been about 
1.3 million diagnoses of breast cancer in women, annually 
(Jemal et al. 2010) and predictions indicate that by 2020, 
we would be watching an upheaved number of new cancer-
ous cases from 10 to 15 million (Hasanpoor Dehkordi and 
Azari 2006; Saki et al. 2011).
Unavoidable risk factors for BC include age and sex, 
which makes the incidence of disease in women 100 times 
more than men, most of them over the age of 55 years. 
In addition, genetic factors contribute to BC susceptibil-
ity. Some of the most important mutations known in BC 
exhibit in the BRCA1 and BRCA2 genes, producing tumor 
suppressor proteins, each of them increases the risk of 
BC in women at age 80 around 70%. Other factors associ-
ated with the incidence of BC include hormone replace-
ment therapy (HRT), hormonal factors (i.e., high level of 
estrogen and progesterone hormones, few experiences of 
pregnancy, short or no periods of breastfeeding, and a later 
menopause), overweight (for post-menopausal breast can-
cer only), utilization of alcohol, low physical activity and 
chest radiotherapy in teen and young adults and owing to 
the assumption of the western lifestyle, the augmentation 
of life expectancy and escalating level of obesity, these 
incidences have been also expected to raise more (Gam-
mon et al. 1998; Colditz et al. 2003; Nelson et al. 2012).
BC is diverse in terms of progression, diagnosis, and 
treatment, and has different classifications. In one of 
the classifications, according to specific cells which are 
affected, BC is divided into carcinoma and sarcoma, and 
in another current classification, BC’s subtypes are iden-
tified by the expression of hormone receptors [estrogen 
receptor (ER), progesterone receptor (PR) and HER2 
(human epidermal growth factor type 2 receptor)] and are 
classified as Luminal (ER+/PR+/HER2−), HER2 sub-
type (ER−/PR−/HER2 overexpression) and Basal-like 
(ER−/PR−/HER2−/basal marker+) including mainly 
triple-negative breast cancers (Nguyen et al. 2017).
Despite the undesirable side effects of the prevalent 
integrated treatments including surgical tumor removal, 
radiation therapy, chemotherapy and biological therapy on 
healthy cells (such as drug resistance, increasing rates of 
osteoporosis in chemotherapy and occurrence of cardiac 
abnormalities during HER2 use or post-menopausal symp-
toms in hormone therapy as well), they have remained 
almost inevitable in the holistic treatment of sophisti-
cated stages of the BC (Normanno et al. 2009). Hence, 
the discovery and expansion of new herbal anti-tumor 
compounds for cancer treatment are of great importance 
for the improvement of combined treatment strategies 
and are the target of numerous investigations (Deng et al. 
2013; Gadhwal et al. 2013; Gibellini et al. 2011). There-
fore, there is a pressing need for investigating and gaining 
more efficient and less toxic compounds for modifying the 
existing untoward condition.
According to preceding explorations, plenty of natural 
products, solely or along with chemotherapy, have the poten-
tial of elevating the effectiveness of the chemotherapeutic 
agents and reducing side effects of conventional therapy 
in several cancers. Hence, new and effective anticancer 
and natural products present a promising supply for such 
approaches (Banerjee et al. 2011; Fridlender et al. 2015).
Flavonoids, as inspiring cancer-preventive nominates, are 
the most investigated compounds among the broad herbal 
chemopreventive compounds and quercetin, as our intended 
compound on this article, is one of the most extensively 
discovered plant-based flavonoids (Neuhouser 2004) which 
can be sufficiently obtained through our daily diet. Querce-
tin (3, 3′, 4′, 5–7 pentahydroxyflavone) with two benzene 
rings combined with a pyrin group in its fundamental con-
struction, is an abundant plant-derived flavonoid in fruits 
and vegetables including onions, apples, legumes, red wine, 
green tea, berries, parsley, and citrus fruits (Chirumbolo 
2010; Li et al. 2016). In addition to anti-inflammatory, anti-
oxidant, anti-allergic (Chirumbolo 2011) and anti-platelet 
aggregation properties, quercetin enclasps anticancer effects 
and possesses impressive inhibitory effects on the growth 
and proliferation of leukemia, breast, ovarian, hepatic, gas-
tric, colorectal, and endometrial cancer cells. Quercetin 
also inhibits invasion, migration, and signaling molecules 
involved in cell survival and proliferation of cancer cell lines 
(Senthilkumar et al. 2011; Lai et al. 2013; Chan et al. 2016; 
Park 2011). According to in vivo and in vitro explorations, 
quercetin applies its anticancer properties by the regulation 
of some specific signaling pathways including the reduction 
of oncogene expression (Ranganathan et al. 2015), regulation 
of the cell cycle (Priyadarsini et al. 2010), apoptosis of malig-
nant cells and reducing the tumors volume (Hashemzaei 
et al. 2017) (Yang and Liu 2009), inhibition of angiogenesis 
(Pratheeshkumar et al. 2012), etc. (Li et al. 2015).
Considering all the appealing benefits makes this com-
pound as a candidate for treating various cancers and dis-
eases with immune pathophysiology. Given the large number 
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of articles available to evaluate the effect of quercetin on 
BC, a complete and comprehensive article summarizing 
this extensive volume of information, comparing similar-
fielded results and categorizing them, does a great job of 
guiding other eager minds to follow this path and, there-
fore, this review article will illustrate the present studies and 
information of quercetin’s efficacy as a natural anti-tumor 
compound for BC’s therapy (Fig. 1).
Apoptosis
Cancer is supposed to be an example of the cell cycle 
deregulation either with an over-proliferation of cells and/or 
reduction of cell removal. Apoptosis defect during carcino-
genesis possesses a vital role in the development, progres-
sion, and resistance to anti-tumor therapies of some cancers 
such as BC. The investigation of the apoptotic defects in 
cancer cells may result in the development of new treatment 
approaches by targeting apoptotic pathways in the cancer 
cells.
Some existing mechanisms by which quercetin exerts its 
effective roles in suppressing the apoptosis process has been 
represented in this section (Fig. 2). Tumor cells have the 
ability to acquire resistance to apoptosis by the expression 
of anti-apoptotic proteins such as Bcl-2 or by the downregu-
lation or mutation of pro-apoptotic proteins such as Bax. 
The expression of both Bcl-2 and Bax is regulated by the 
p53 tumor suppressor gene (Miyashita et al. 1994). There-
fore, the anticancer effects of many existing medicines are 
through the induction of apoptosis. In the following, we 
would represent the studies investigating quercetin’s effects 
on cell cycle and apoptosis.
Fig. 1  Different aspects of quercetin’s affection. Quercetin increases 
apoptosis, cell cycle arrest and some receptors expression and on the 
other hand decreases cell proliferation, drug resistance, metastasis 
and angiogenesis. There have been controversial results about querce-
tin’s effect on oxidative stress
Fig. 2  Quercetin-induced apoptosis. Quercetin (Q) can induce apop-
tosis in extrinsic, intrinsic and common pathways by increasing the 
activators, suppressing the inhibitors and regulators and increasing 
mRNA of ligands bound to apoptotic receptors. However, some of 
them, including cytochrome c, in some articles and in different cancer 
cell lines, were contradictory
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It has been stated that quercetin is able to inhibit prolifer-
ation, decrease cell viability and induced apoptosis in treated 
cancer cells in a dose-dependent manner through increasing 
the DNA histogram of the G0/G1 apoptotic subpopulation 
and decreasing the S phase subpopulation, without no dif-
ference in the G2/M subpopulation in MCF-7 and BT-474 
(HER2 overexpressing) cell lines (Dhumale, Waghela, and 
Pathak 2015; Li et al. 2018c; Seo et al. 2016). Quercetin 
arrests cell growth via increasing S and G2/M subpopula-
tions and 30% decreasing G0/G1 subpopulation in the tri-
ple-negative MDA-MB-231 cell lines (Nguyen et al. 2017). 
Furthermore, quercetin can decline cell viability in sorted 
stem cells (CD44+/CD24−) in vitro and reduce the capabil-
ity of metastasis and tumorigenesis in vivo (Li et al. 2018c).
There are noticeable inconsistencies in the literature 
regarding apoptosis induction in the intrinsic or extrinsic 
pathways by quercetin. It has been reported that querce-
tin reduces the expression of mitochondrial cytochrome c, 
procaspase-7, anti-apoptotic protein Bcl-2 level, and mito-
chondrial membrane potential (ΔΨm); quercetin-induced 
apoptosis is mediated by a mitochondrial-dependent path-
way in MCF7 cell line (Dhumale et al. 2015). The study by 
Khorsandi et al. has proved the quercetin’s role in suppress-
ing MCF-7 cells growth, inducing apoptosis by the enhance-
ment of Bax and reduction of Bcl2, and stimulating necrop-
tosis signaling pathways (Khorsandi et al. 2017). In the same 
way in another study, by the measurement of (ΔѰm), Bcl2 
and BAX loss, it has been indicated that quercetin is unable 
to induce the intrinsic pathway of apoptosis but induces 
apoptosis via the extrinsic pathway in BT-474 breast cancer 
cells (even in the presence of inhibitors) and, therefore, it 
has been found that quercetin induces the caspase-dependent 
mechanism of apoptosis in BT-474 cells (Seo et al. 2016). 
Others have shown that quercetin elevates the expression of 
FasL, P53, GADD45, P2, and FOXO, which are involved 
in apoptosis regulation and cell cycle arrest, in an MDA-
MB-231 cell line (Nguyen et al. 2017). Cotreatment of 
quercetin with rhTRAIL has stated that quercetin by upreg-
ulating caspase 7 and 8, cytosolic cytochrome C, cleaved 
PARP and downregulating Bid, contributes to the enhance-
ment of rhTRAIL-mediated apoptosis through both intrinsic 
and extrinsic pathways. Further details have been mentioned 
in the drug resistance section (Manouchehri et al. 2018).
Numerous studies have evaluated the effects of quercetin 
plus nanoparticles on apoptosis and proliferation. AuNP, as 
a nanoparticle used for the improvement of drug delivery, 
conjugates with quercetin and their combination is able to 
enhance apoptosis (Balakrishnan et al. 2017). In a study by 
Aghapour et al. using silica—nanoparticle to the promot-
ing quercetin’s efficacy, it has been observed that quercetin 
nanoparticles inhibit the MCF-7 proliferation in lower con-
centration and earlier time zones and quercetin nanoparticles 
would be able to act more effectively (Aghapour et al. 2018). 
In another study to the improvement of quercetin’s potential, 
vanadium had been used and suggested that vanadium + 
quercetin exhibited a higher percentage of early apoptotic 
cells in MCF-7 cell lines and notable upregulation of P53, 
caspase 3, caspase 9 in a dose and time-dependent manner 
as compared to the control (Roy et al. 2018).
In addition to quercetin’s direct effects on the apoptosis 
pathways, it can affect apoptosis by affecting other mecha-
nisms. For instance, the receptor for advanced glycation 
end-products (RAGE) is a signaling receptor of the immu-
noglobulin superfamily which interacts with ligand high-
mobility group box-1 (HMGB1) and has recently been 
reported that their binding is involved in the promotion of 
tumor microenvironment, metastasis, and cell proliferation. 
Previous studies have indicated that the inhibition of this 
receptor suppresses tumor growth and metastasis in animal 
models (Harris and Andersson 2004). In quercetin-treated 
cells, reduced expression of RAGE and HMGB1 has been 
observed and also it has been stated that quercetin pro-
tects from necrotic hurts through the inhibition of HMGB1 
release (Dhumale et al. 2015).
Since miRNA has the regulatory role in translation 
and almost 50% of them are related to tumor genes (Jing 
and Chen 2014), their association with quercetin has been 
investigated in the study conducted by Tao et al. This study 
showed that quercetin can inhibit the growth of MCF-7 and 
MDA-MB-231 cell lines by upregulating miR-146a expres-
sion, resulting in the enhancement of the Bax and caspase 3 
expression (Tao et al. 2015) (Fig. 2). Generally, it is likely 
that quercetin increases apoptosis and plays a positive role 
in the treatment, development, and progression of breast 
cancer.
Cell cycle
Cell proliferation is controlled by the precise mechanisms of 
the cell cycle and the checkpoints. In proliferating cells, dis-
tinct cyclin-dependent kinases (CDKs) are activated in com-
plexes with specific cyclins and subsequently help the cells 
in transition between consecutive phases of the cell cycle by 
inducing phosphorylation. Aberrant expression or altered 
activity of these complexes results in the escape of cells from 
the cell cycle control and leads to malignant transformation. 
Therefore, the effectiveness value of different treatments on 
cancers is determined by the effect on factors contributing to 
the cell cycle regulation. In line with this notion, some reports 
are pointing to the effects of quercetin treatment on cell cycle 
arrest and the expression of cell cycle regulators. Quercetin 
(40 µM/mL) in 24 h exposure to MCF-7 cell line, which is 
a widely studied model for hormone-dependent human BC, 
causes apoptosis and reduces cell viability and proliferation. 
Hence, these changes indicate the disturbance in the cell cycle 
process. Furthermore, it has been shown that quercetin (40 µM/
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mL) induces cell cycle arrest in G1 and results in the accumu-
lation of the cells in this stage when compared to control. Other 
results of this study showed that quercetin (40 µM/mL) slightly 
inhibited the cell cycle on S phase, while it was not effective 
on apoptosis and proliferation in triple-negative breast cancer 
cell line of MDA-MB231 (Ranganathan, Halagowder, and 
Sivasithambaram 2015; Wu et al. 2018a). In contrast, others 
have indicated that increasing the incubation time of MDA-
MB231 cell line with quercetin (15 and 20 µM/mL) to 48 h, 
as well as increasing the concentration up to 100 μM in 24 h, 
was sufficient for the cell cycle arrest of this cell line in the 
G2/M and S phases (Nguyen et al. 2017; Rivera et al. 2016; 
Wang et al. 2018). 48 h of incubating MDA-MB435 (her2 + 
cell line) with 15 µM/mL quercetin has also shown cell cycle 
arrest in the G2/M phase (Rivera et al. 2016). In fact, querce-
tin inhibits the proliferation and reduces the cell viability by 
affecting the signaling proteins involved in the expression of 
the genes and proteins of cell cycle regulators. In this regard, 
quercetin increases apoptosis and cell cycle arrest by increas-
ing the activity of Foxo3a signaling protein and its upstream 
protein (JNK) which are apoptotic and cell cycle regulators. 
Besides the effects on signaling proteins, quercetin increases 
the activity of the cell cycle regulatory proteins P53, P21, and 
GADD45 in BC cell lines (Nguyen et al. 2017; Ranganathan 
et al. 2015). The observed cell cycle arrest at different phases 
could be due to the inhibition of different cell cycle checkpoint 
proteins by quercetin. In a study conducted by Ranganathan 
et al., it has been reported that incubation of MCF-7 cell line 
with quercetin leads to the cell cycle arrest in the G1 phase and 
reduction in the expression of cyclinD1 protein, which is an 
effective checkpoint for crossing this stage (Ranganathan et al. 
2015). Although the ability of quercetin in cell cycle arrest 
has been proved by examinations of various breast cancer cell 
lines, the precise mechanism of this function and its effects 
on cell cycle’s checkpoints still require more studies (Fig. 3).
Drug resistance
Among the enormous utilizing treatments for BC, chemo-
therapy is of great importance in clinical cancer therapy. 
Intrinsic or acquired multidrug resistance (MDR) is a major 
obstacle impediment to efficacious chemotherapy and 
despite consuming various drugs such as cyclosporine A 
and verapamil (which act by binding to p-gp) for MDR over-
coming, the existing side effects had restricted their clini-
cal usage (Ji et al. 2005). Across the multiple mechanisms 
contributing to the MDR phenomenon, several factors can 
be pointed out, including tumor vascularization and angio-
genesis, variation in the specific enzyme systems activity, 
deregulation of apoptosis, active drug extrusion by ATP-
binding cassette (ABC) transporters and so on.
Among the offered mechanisms responsible for MDR 
development, a great number of researches have been accom-
plished on the excessive expression of ABC transporters.
Further detailed analysis revealed that P-glycoprotein 
(P-gp, ABCB1), multidrug resistance-associated protein 
1 (MRP1, ABCC1) and breast cancer resistance protein 
(BCRP, ABCG2) contribute to the reduction of cellular 
drug accumulation by drug effluxion. Hence, the enhanced 
efficacy of chemotherapy would be an outcome of ABC 
Fig. 3  Quercetin (Q) effect on cell cycle. Multiple checkpoint exists 
in cell cycle to ensure that division and proliferation occur in the cor-
rect way in cells. Cyclins and CDKs come together for progressing 
this cycle and these proteins are regulated by the other proteins such 
as P21, P27 and P57. Quercetin by beneficial effect on these protein 
helps to regulate cell cycle in cancers
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transporter inhibition (Ambudkar et al. 2003; Litman et al. 
2001).
• Doxorubicin (DOX), a chemotherapeutic agent belong-
ing to the anthracycline family which stops or slows the 
growth of cancer cells by blocking the topoisomerase 
2 enzyme, is considered as a substrate of P-gp protein. 
Long-term consumption of DOX would enhance the tran-
scription of the MDR-1 gene in MCF-7 cells and subse-
quently upregulate the expression level of P-gp, leading 
to the development of DOX-resistance and finally the 
poor therapeutic outcome would be accomplished (Chai-
komon et al. 2018).
• It has been reported that polyphenolic compounds such 
as quercetin, with high selectivity and low toxicity, can 
directly interact with several ABC transporter proteins 
leading to the inhibition of drug efflux mediated by either 
p-gp or MRP1 or BCRP. In addition, it enhances the 
uptake of chemotherapeutic agents in cancer cells and 
restrains P-gp expression by variation in the cell mem-
brane penetrance, reduction of P-gp expression, spe-
cific binding to P-gp protein and other mechanisms and, 
accordingly, acts as a chemosensitizer for MDR reversal 
on plenty of cells showing MDR including MCF/MR cells 
and augments the efficacy of chemotherapeutic drugs.
• Some reports have indicated that the combination of 
quercetin with Dox, at all combination ratios, represents 
synergistic inhibitory effect against MCF-7 breast cancer 
cell line and attenuated unwanted cytotoxicity on non-
tumoral cells (Purba and Astuti 2013). These results were 
consistent with another research Staedler et al. which 
has indicated much reduction of DNA strand breaks and 
damage in non-tumoral cells than in tumor cells by this 
combination and, therefore, claimed the protective role 
of quercetin (Staedler et al. 2011).
• The improvement of cancer cell sensitivity to Dox and inhi-
bition of proteins expression encoded in the MDR1 gene 
such as P-gp, MRP, and BCRP by this flavonoid had been 
proved. Due to the lower expression of P-gp in MCF-7/
dox75q750 rather to MCF-7/dox75 cells and the absence 
of P-gp expression downregulation in MCF-7 cell in the 
quercetin exposure, it has been concluded that the observed 
effects by quercetin may be represented via another mecha-
nism of action, perhaps by affecting the transportation of 
Dox and not by the downregulating P-gp expression. There-
fore, increased Dox concentration in the cell may contribute 
to the lack of P-gp expression, leading to the induction of 
apoptosis (Desrini and Sholikhah 2017).
• Besides the development of BC cells resistant to Dox, 
long-term consumption of DOX can contribute to a 
potent toxic side effect on non-cancerous cells and tis-
sues, especially on myocardial cells. Interestingly, the 
combination of a nontoxic dose of quercetin with DOX 
has the potential to strongly increase the Dox cytotoxic-
ity to breast cancer MCF-7 and MDA-MB-231 cells and 
decrease the Dox cytotoxicity to normal mammary cells 
and myocardial cells on the contrary. The above combi-
nation exhibits a light impact on P-gp, BCRP and MRP1 
expressions in non-cancerous MCF-10A mammary cells 
and myocardial AC16 cells (Li et al. 2018a).
• Lately, mounting documents have highlighted the role of 
YB-1 nuclear translocation in P-gp overexpression and 
BCSCs (Breast Cancer Surveillance Consortium) pheno-
type (CD44+/CD24−/low) development, leading to the 
Dox-resistance of BC cells. YB-1, defined as a nuclear 
transcription/splicing and a cytoplasmic mRNA binding 
and stabilizing factor with several localization-depend-
ent functions, has been identified as a basic factor in 
many malignant cancers. They have proved much higher 
expression of YB-1 nuclear protein and P-gp, as well as 
the CD44+/CD24−/low phenotype in MCF-7/dox cells 
comparing to MCF-7 cells. As expected, cells with high 
expression of the mentioned factors are resistant to vari-
ous chemotherapeutic drugs including Dox, Vincristine 
(Ver), and Paclitaxel (Pac). According to their results, 
the nontoxic dose of quercetin has the inhibitory poten-
tiality to YB-1 nuclear translocation induced by three 
suggested chemotherapeutic drugs and can enhance the 
chemosensitivity of MCF-7 and especially MCF-7/dox 
cells to Dox, Pac, or Vcr. The apoptosis of MCF-7 and 
MCF-7/dox cells would be more remarkably increased 
by Dox + quercetin combinatory therapy rather to Dox 
treatment alone. They also noted the synergizing role of 
quercetin with Dox, Pac, or Vcr in BCSCs elimination, 
which exhibit cancerous characteristics besides stem cell 
self-renewal, in MCF-7 and MCF-7/dox cells (Li et al. 
2018b).
• In a recent study, treatment with quercetin and vitamin 
C in combination with DOX and PAC has been studied. 
Lower CI values and much decrease in IC50 values of 
BC cells exposed to this combination therapy led them 
to this conclusion that their novel therapy has powerful 
synergism and can enhance the chemosensitivity of BC 
cells. In addition, the application of chemotherapeutic 
drugs along with a multiple signaling inhibitor (querce-
tin) and an antioxidant agent (vitamin C) may contribute 
to reduce the side effects and similarly the administrated 
dose of chemotherapeutic drugs (Ramezani et al. 2017). 
Moreover, probably due to the relative enhancement of 
quercetin’s stability in nearby tumor cells, the higher effi-
cacy of quercetin-nanostructures accompanied by Dox 
would be well clarified (Minaei et al. 2016).
• Tamoxifen, a first-line endocrine therapy, is another 
chemotherapeutic agent that competitively binds to ER 
and, therefore, hampers BC cells growth. Long-term 
administration of tamoxifen would contribute to MDR in 
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40% of cases but its underlying mechanism is intricate and 
most of the attention of the ongoing surveys have been 
absorbed to abnormal activation of growth factor signal-
ing pathways and the reduction or loss of ERα (Tanic et al. 
2012; Zhang et al. 2012a). Interesting research with three 
doses of quercetin and three different quercetin durations 
of exposure on MCF-7Ca/TAM-Resistant cell line was 
carried out in 2015 based on the mentioned information. 
According to their results, all doses of quercetin, in differ-
ent time exposures, had a significant potent in decreasing 
the cell survival rate (CSR) (in a dose- and time-dependent 
manner). Furthermore, their results revealed that 50 µM/
mL quercetin exerts a significant effect on enhancing 
the apoptosis level. The authors have also observed the 
downregulation of Her-2 expression and the upregulation 
of ERα when enhancing quercetin’s dosage and, hence, 
quercetin has the potential to block the regulatory crosstalk 
between signaling pathways mediated by ERα and Her-2, 
leading to the reversion of tamoxifen resistance in MCF-
7Ca/TAM-R cells (Wang et al. 2015).
• Another related study on tamoxifen resistance showed 
the significant inhibitory effect on MCF-7 cell prolifera-
tion, following treatment with a lower concentration of 
quercetin-tamoxifen. It is reported that tamoxifen admin-
istration accompanied by quercetin leads to a remarkable 
decrease of cell viability and induces apoptosis via the 
mitochondrial pathway in multidrug-resistant MCF-7 
cells through inducing mitochondrial enzymes, activating 
caspase-3, altering the expression of anti-apoptotic Bcl-2 
and pro-apoptotic Bax proteins (Kavithaa et al. 2014).
• In a recent study on the co-delivery of quercetin with a 
chemotherapeutic agent of metastatic cancers (docetaxel, 
DTX) for the purpose of metastasis and growth inhibi-
tion of breast cancer cells, hyaluronic acid (HA)-modified 
nanoparticles (NPs) were used as vectors to block metas-
tasis (PP-HA/NPs). DTX blocks mitotic spindle division 
by promoting microtubule polymerization and inhibiting 
tubulin depolymerization. It can inhibit cell growth and 
induce cell apoptosis, and its synergism with quercetin 
enhances its cytotoxicity and improves the cell cloning 
inhibition which might correlate with the PI3 K/Akt path-
way. As we know, MMP-9 is a major matrix proteinase, 
able to inhibit Akt phosphorylation and consequently its 
own expression and also by degrading the extracellular 
matrix (ECM is positively associated to tumor metasta-
sis (Andreasen et al. 1997; Wang et al. 2017). Accord-
ing to this information, this paper has stated that PP-HA/
NPs inhibits cell migration and invasion by initiating the 
Akt/MMP-9 signaling pathway, downregulates p-Akt and 
MMP-9 expression and induces cell apoptosis. HA coating 
and its modification has got an undeniable role in abort-
ing the effects of p-gp which effluxes docetaxel and this 
happens, by the active targeting property via HA–CD44 
interaction, CD44 receptor-mediated endocytosis and thus 
promoting cellular uptake of drug and its accumulation in 
tumor cells, has got an undeniable role in abrogating the 
effects of P-gp, which effluxes docetaxel (Li et al. 2017).
• Rutin (Qu 3-O-β-d-rutinoside) is an anticancer adjuvant 
that in combination with cyclophosphamide (CYC) and 
methotrexate (MTX) enhances their efficacy and cyto-
toxicity against MDA-MB-231 BC cell line. Previous 
studies have shown that this adjuvant improves the drug 
efflux and promotes programmed cell death, thereby 
leading to the drug resistance impairment in cancer cells 
(Iriti et al. 2017).
• Everolimus, a rapamycin analog classified as an allosteric 
inhibitor of mTOR complex 1 (mTORC1), is another 
potent cytotoxic chemotherapeutic molecule (Aapro et al. 
2014). mTOR inhibition blocks the translation of genes 
regulating the proliferation of cancer cells and leads to 
the induction of certain cell growth factors which con-
tributes to the formation of new blood vessels. Studies 
on the anti-inflammatory, anticancer properties and cel-
lular uptake of quercetin and everolimus combination had 
emphasized the significance of this combination and its 
synergism in the regulation of MCF-7 cell proliferation 
and highlighted the anti-tumor properties of these mol-
ecules (Quagliariello et al. 2017).
• The optimized formation of the endogenous death ligand 
TRAIL, called recombinant human tumor necrosis fac-
tor-related apoptosis-inducing ligand (rhTRAIL), is a 
remarkable potential anticancer treatment. The consid-
erable attention gained to this treatment may be partially 
attributed to its ability of inducing apoptosis in cancer 
cells, while exhibiting minimal toxicity to normal, non-
transformed cell (Shen et al. 2004; Turner et al. 2017); 
Some reports have demonstrated that quercetin, as a 
possible sensitizing agent, has the potential to conquer 
rhTRAIL-resistance turned up in almost every breast 
cancer cell, followed by the upregulation of anti-apop-
totic proteins, including c-FLIP, a major inhibitor of the 
extrinsic pathway (Jung et al. 2010; Kim et al. 2008). 
Already published literature has provided evidence that 
quercetin + rhTRAIL cotreatment, by sensitizing BC 
cells to rhTRAIL-induced apoptosis through the induc-
tion of the extrinsic pathway of apoptosis, is efficacious 
for hormone dependent and triple-negative BC and also 
for the enhanced ubiquitination and proteasome-medi-
ated degradation of c-FLIPL by quercetin. It has been 
brought up as a novel underlying mechanism to facilitate 
the enhanced rhTRAIL sensitivity and downregulate the 
long form of c-FLIP (c-FLIPL), the caspase 8 inhibitor 
(Manouchehri et al. 2018).
• Another commonly used anticancer drug for BC is cis-
platin according to existing evidence, its long-term uti-
lization can develop the cisplatin resistance, especially 
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due to excessive expression of human cytochrome P450 
CYP1B (McFadyen et al. 2001). Results achieved by 
Sharma et al. provided evidence of quercetin’s potential 
role in inhibiting CYP1B1 enzyme (selectivity toward 
CYP1, not CYP2 and CYP3 family of enzymes), leading 
to its cisplatin-resistance reversal activity (Sharma et al. 
2017).
• Additionally, a recent literature had investigated the 
synergistic effects of cisplatin + quercetin in an in vivo 
EMT6 tumor-bearing mice model of BC. Based on 
their obtained results, they concluded that quercetin co-
administration with cisplatin (30 mg/kg+7 mg/kg), by 
reducing the oxidative damage of renal tissue, decreas-
ing serum BUN and creatinine levels and increasing the 
γ-glutamyltranspeptidase GGT and alkaline phosphatase 
AP activity, exerted anti-tumor activity and reduced the 
tumor size by 54%, while quercetin by itself was ineffec-
tive at 30 mg/kg and cisplatin administration alone (7 mg/
kg) resulted in 29% inhibition of tumor growth (Liu et al. 
2019). On the other hand, since Sánchez-González et al. 
reported that quercetin did not affect anti-tumor activ-
ity of cisplatin in breast tumor cell (13762 Mat B-III) 
in rat model only by one-time injection of cisplatin 
(Sánchez-González et al. 2017), it can be concluded that 
quercetin’s affection seems to be more outstanding when 
administered with multiple doses of cisplatin rather than 
a single dose.
Metastasis
Metastasis is a complex, multistep process during which 
tumor cells acquire the characteristics necessary to escape 
their original environment and transfer to distant sites 
through the blood stream. In this situation, the treatment will 
be difficult and the mortality rate in patients will increase. 
Regarding the complexity of the factors affecting metastasis 
and the importance of inhibiting these factors in the treat-
ment of cancers, several factors have been investigated on 
the quercetin and metastasis experiments.
The incidence of angiogenesis in metastasis is followed 
by increased serum vascular endothelial growth factor 
(VEGF) levels. The VEGF secreted from cancer cells bind to 
VEGFR2 and trigger the transmission of NFAT/AKT/PI3K 
and MAPK signaling pathways which results in the replica-
tion of angiogenesis effective genes such as VEGF/VEGFR/
COX. After exposing tamoxifen-resistant MCF-7 cell line 
with different flavonoids in the cell culture, more effective 
results in reducing VEGF production were observed from 
quercetin compared to other flavonoids. An in vivo study on 
cancerous female BALB/c nude mice showed that injection 
of quercetin in addition to serum VEGF reduction prevents 
tumor growth after 21 days and reduces its volume in com-
parison to the control group. Furthermore, this compound 
increases the incidence of necrosis by reducing the prolifera-
tion of cells in the tumor site. Quercetin’s ability to inhibit 
angiogenesis was confirmed by decreasing the expression 
of Von Willebrand factor (VWF) (the blood glycoprotein 
involved in hemostasis, bleeding, and angiogenesis) in the 
tumor tissue with IHC test. Ex vivo and in vitro assays have 
shown the inhibiting ability of quercetin on new blood vessel 
formation and angiogenesis. By reducing the expression of 
the VEGFR2 protein in the tumor tissue, quercetin decreases 
the expression of AP-1, NFATC3 (the activated form of 
NFAT), and HIF-1α transcription factors and also pin-1 
enzymes which all are effective in the expression of angi-
ogenesis-related genes (Oh et al. 2010; Zhao et al. 2016).
In metastasis, migration and invasion of cancer cells are 
also of great importance. In the invasive form of breast can-
cer such as basal-like subgroup, WNT/βcatenin nuclear sign-
aling pathway is activated and triggers c-myc and cyclinD1 
gene expression. c-myc is believed to regulate different 
gene expressions and acts as a regulator in the migration 
and invasion of tumor cells in which its level rises in the 
invasive BCs. Cell culture of triple-negative cell lines with 
different doses of quercetin for 24 h, indicated the accumula-
tion of βcatenin in the cytoplasm (decreasing the activity of 
this signaling pathway) compared to the control group and 
thereby reduced the gene and protein expression of c-myc 
and cyclinD1 (Srinivasan et al. 2016).
Matrix metalloproteinases (MMPs) are the family of pro-
teolytic enzymes that play a definitive role in tissue remod-
eling, angiogenesis, and aid in breaching the basement mem-
brane, thus leading to tumor invasion and metastasis. The 
study on quercetin with gold nanoparticle drug delivery has 
shown that quercetin inhibited MMP-2 and MMP-9 protein 
expression in BC cell lines (Balakrishnan et al. 2016; Jia 
et al. 2018).
It has been proved that quercetin is able to directly/
indirectly inhibit migration and invasion in BC stem cells 
through the inhibition of some factors which have indispen-
sable role in cancer deterioration including aldehyde dehy-
drogenase 1 family member A1 (ALDH1A1), CXCR4 (an 
alpha-chemokine receptor specific for C-X-C motif ligands 
(CXCLs)), epithelial cell adhesion molecule (EpCAM), and 
Mucin1 (MUC1) (Wang et al. 2018).
Epithelial–mesenchymal transition (EMT) is recognized as 
a critical event for metastasis of carcinomas and is the main 
reason for promoting metastasis in epithelium-derived cancer 
cells. These epithelial cells enhance the N-cadherin expression 
and decrease E-cadherin expression, which is a well-known 
tumor suppressor and cell adhesion molecule, thereby losing 
the polarity and obtaining the ability to invade to the other 
parts of the body. The expression of the E-cadherin molecule 
is controlled by the slug, snail and twist transcription fac-
tors. In cancer cells, reduction in the expression of E-cadherin 
occurs by increasing the expression of these transcription 
48 N. Kasiri et al.
1 3
inhibitory factors. Studies have shown that exposing querce-
tin to various kinds of BC cell lines reduces the expression 
of slug, snail and twist transcription factors as well as N-cad-
herin, while increasing the expression of E-cadherin. Increas-
ing the vimentin protein indicates EMT incidence because 
this structural protein is expressed in mesenchymal cells. 
Anticancerous effects of quercetin reduce the vimentin gene 
and protein expression. These findings suggest that quercetin 
can act as an EMT event inhibitor (Balakrishnan et al. 2016; 
Ranganathan et al. 2015; Srinivasan et al. 2016).
Increase in glucose uptake and reduction of autophagy 
are two important factors for the migration and mobility of 
cancer cell. Increase in the activity of the Akt–mTOR sign-
aling pathway leads to the improved glucose uptake and 
reduced autophagy of cancer cells, which both contribute to 
the metastasis and invasion of these cells. It has been shown 
that quercetin is able to suppress the Akt–mTOR pathway 
by inhibiting the Akt, mTOR, p70s6k phosphorylation and 
increasing AMPK which is a negative regulator of mTOR 
signaling (Jia et al. 2018; Rivera et al. 2016; Pratheeshkumar 
et al. 2012). Quercetin is additionally useful in reducing glu-
cose consumption in cancer cells, by reducing the expression 
of the glucose transporter 1 (GLUT1), lactate dehydrogenase, 
pyruvate kinase isozyme M2 (PKM2) and glyceraldehyde-
3-phosphate dehydrogenase (GADPH) proteins. Querce-
tin influences glucose consumption through suppressing 
glucose uptake and reducing lactate level in MDA-MB-231 
and MCF-7 cell lines. Quercetin suppresses glycolysis and 
induces autophagy in the in vivo model of BC by reducing 
the phosphorylation of PKM2 and AKT and increasing beclin 
1 (which is an autophagy marker) in tumor tissue (Jia et al. 
2018). In addition, quercetin prevents the deterioration and 
risk of cancer death by controlling the factors involved in the 
incidence of EMT, invasion, migration, and angiogenesis that 
all contribute to the metastasis of cancer cells (Fig. 4).
Oxidative stress
In physiological conditions, there is a fine balance between 
the reactive oxygen species (ROS) and anti-oxidants produc-
tion in cells which is disturbed by oxidative stress occur-
rence. Oxidative stress is a circumstance in which the level 
of ROS exceeds the cellular anti-oxidant capacity and causes 
the proliferation enhancement, signaling pathways activity 
and genomic instability which are all hallmarks of cancer. 
In cancer, the disturbance of ROS and anti-oxidants balance 
occurs by the alteration in antioxidant function depending on 
type and time of cancer; for example, during the progression 
of human BC, anti-oxidants activities decrease and the ROS 
accumulation leads to cancer cells mutation and proliferation 
while in the late stage, we would be watching an increase in 
Fig. 4  The most important events in metastasis occurrence. Quercetin (Q) by effectual impact on different metastasis related factors (inhibitors 
and activators) prevents metastasis
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anti-oxidant activity to combat ROS and promote carcino-
genesis without chemotherapy responding.
Given the importance of balancing ROS and anti-oxi-
dants in the prevention of cancer, the use of supplements 
and therapies for achieving this balance is a priority in the 
treatment and prevention of cancer. In line with this notion, 
quercetin is known as an antioxidant flavonoid compound 
that has anti-oxidant and pro-oxidant properties, depending 
on the dose and exposing time (Devi et al. 2014).
In a study of comparing the cytotoxicity of quercetin 
with its glycosylated forms in inhibiting tumor cell growth, 
it has been observed that quercetin, more than its glyco-
sylated form, induces MCF-7 cell line apoptosis by increas-
ing the accumulation of O−
2
 and H
2
O
2
 free radicals (Wu et al. 
2018a). This free radical accumulation also occurs when 
exposing MCF-7, MDA-MB-231 and MDA-MB-468 cells 
to quercetin and Vitamin C combination (Mostafavi-Pour 
et al. 2017). On the contrary, another study has indicated that 
quercetin leads to the inhibition of ROS and NO in MCF-7 
cells stimulated by lipopolysaccharide (LPS) to produce free 
radicals (Quagliariello et al. 2017).
In BC, the Nrf-2 transcription factor, which is responsible 
for maintaining redox hemostasis, is activated by separating 
from its inhibitory part, keap-1(Kelch-like ECH-associated 
protein 1) and translocates into the nucleus to induce the 
expression of cells protective genes. This event leads to the 
better progression of triple-negative BC, while in the ER+ 
type, Nrf-2 induction by increasing NQO1 (NADPH dehydro-
genase Quinone 1), decreasing ROS, and also reducing the ER-
dependent proliferation leads to the better prognosis cancer.
In the study conducted by Minaei et al., it has been shown 
that the use of quercetin in 75 µM/mL concentration did not 
affect the expression of the Nrf-2 gene, but the expression 
of the downstream genes of this transcription factor, namely 
MRP-1 (multidrug resistant-associated protein), which pro-
vides drug resistance to cancer cells, and also NQO1, which 
has a protective effect on cells, had been declined by querce-
tin that it could be beneficial in sensitizing cancer cells to 
chemotherapy (Minaei et al. 2016).
Although quercetin failed to reduce the expression of Nrf-
2, its combination with vitamin C reduced the expression of 
Nrf-2 protein and HO-1 activity in MCF-7, MDA-MB-231, 
and MDA-MB-468 (Mostafavi-Pour et al. 2017).
Previous studies have indicated that quercetin’s effects on 
oxidative factors depend on the involved tumor tissue, time 
exposure, and dose. In a study considering quercetin’s effect 
on cardiovascular protection, which is a vulnerable member 
to oxidative stress, it was observed that quercetin recovered 
GSH content in the heart tissue and reduced the lipid hydro 
peroxidase and also reduced the overall activity of SOD and 
CuZnSOD (exist in red cells). These observations show that 
quercetin acts better in protecting the heart against oxida-
tive stress rather to pirolin (Tabaczar et al. 2015). Therefore, 
depending on condition, quercetin has anti-oxidant and pro-
oxidant properties, to balance the free oxygen radicals and 
anti-oxidants to block the cancerous situation to physiologi-
cal conditions.
Receptors
Estrogens influence the physiological conditions in females 
via the receptors which express on different organs such as 
the uterus, vagina, ovaries, and mammary gland. Estrogens 
are considered as a risk factor for the development of BC, 
although molecular mechanisms involved in this suscepti-
bility are not well clarified so far. Several mechanisms have 
been proposed to the role of these hormones in the risk of 
BC. Some studies have indicated that certain metabolites 
of estrogen can bind to DNA and induce mutations. Others 
have mentioned the role of estrogens in stimulating breast 
epithelial cell proliferation. To support this, it is demon-
strated that BC cells express estrogen receptor alpha (ERα) 
upon proliferation which lead directly to estrogen effect on 
the growth of BC cell (Duffy 2006).
ERα and ERβ are two gene transcription regulators pos-
sessing physiological roles in BC process. Estrogen, via 
bonding to ERɑ and ERβ, affects the DNA and target genes. 
These receptors have opposite effects on proliferation; ERɑ 
usually has a proliferative response while ERβ is anti-pro-
liferative (Powell et al. 2012). Generally, these receptors can 
be important in the treatment of BC.
In the same way, endocrine therapy is usually preferred 
because of reducing recurrence and metastasis in ER-
positive patients (Wang et al. 2015). Studies on BC have 
proved that Her-2 may agitate the MAPK pathway to induce 
phosphorylation of ERɑ, resulting in the growth of tumor 
cells (Brodie et al. 2005). It has been emphasized that down-
regulation or loss of ERα and disturbance in the signaling 
pathway of growth factors induces drug resistance to tamox-
ifen. There are some reports that quercetin, in high concen-
trations, had the ability to downregulate Her-2 expression 
and upregulate ERα in MCF-7Ca/TAM-R cell line. Hence, 
quercetin can inhibit the signaling pathways mediated by 
Her-2 and thereby reduces the drug resistance to tamoxifen 
(Wang et al. 2015). Furthermore, the study conducted by 
Wilkinson et al. has shown that quercetin (30 µM/mL) acti-
vates ERα in Cos-7 cells, while this effect was not observed 
on ERβ (Wilkinson et al. 2015).
Quercetin derivatives
Anticancer effects
For the purpose of finding probable clinical chemotherapeutic 
drugs, efforts using modified quercetin analogs in breast can-
cer treatment had been augmented over the past recent years.
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According to a study conducted by Bao et al. on the 
cytotoxicity of 8 derivatives of quercetin [including 
7-O-ButylQu (BQ), 3,7-O,O-dibutylQu (DBQ), 7-O-gera-
nylQu (GQ), 3,7-O,O-digeranylQu (DGQ), 7-O-allylQu 
(AQ), 3,7-O,O-diallylQu (DAQ), 7-O-cinnamylQu (CQ), 
and 3,7-O,O-cinnamylQu (DCQ)] (Fig.  5.) on MCF-7 
cells, the authors indicated that the strongest cytotoxicity 
effects on MCF-7 cell lines were exerted by BQ and GQ 
and among them, GQ was the most toxic derivative; In 
line with this area, more investigations on the cytotoxic 
effect of GQ on other cancerous cell lines have been done 
and indicated that GQ is a cytotoxic compound with wide 
spectrum and might attract much attention in the chemo-
therapy field, so on. Also, it has been demonstrated that 
longer substituent group for 7-O-monoalkyl derivatives 
promotes their cytotoxicity and this possibility is that this 
phenomenon might have connections to the compound’s 
lipophilicity and their cell permeability (Bao et al. 2016).
Previous researches indicated that quercetin intesti-
nal absorption cannot happen in its native form and its 
metabolization into various sulfated, glucuronidated and 
methylated forms occurs in different organs, including 
liver, kidney, colon, and small intestine, suggesting that 
its metabolites by possessing higher hydrophilic features, 
may act as better anti-oxidants than its native form (Wic-
zkowski et al. 2014; Yeh et al. 2016).
Concordant results by 2 published paper from Wu et al. 
revealed that quercetin and its metabolites including IS 
(isorhamnetin), I3G (isorhamnetin-3-glucuronide), Q3′S 
(Qu-3′-sulfate sodium salt) and Q3G (Qu-3-glucuronide 
sodium salt) (Fig. 5) inhibit hyperplasia of tumor cells and 
induce apoptosis and necrosis of MCF-7 cells both in in vivo 
and in vitro which are mainly mediated by cell detention 
in the S-phase and reduction in the number of cells in G0/
G1 and G2/M phases of the cell cycle (with the potency 
ranked in these two different papers as quercetin > IS > I3G 
and quercetin > Q3′S > Q3G). In addition, their anti-tumor 
mechanism may also be associated with their membrane 
penetration ability and assist their cytotoxic activity. Their 
strong cytotoxic effects may be applied through an ROS-
dependent apoptosis pathway in MCF-7 cells and they have 
also confirmed that 3′-methylation would reduce querce-
tin’s cytotoxic properties, 3-glucuronidation would further 
reduce the cytotoxic activity of IS (3′-methylated form of 
quercetin), and group replacement at the 3′-OH and 4′-OH 
positions may have a remarkable reduction in quercetin’s 
antioxidant activity. These findings exhibit the relationship 
between the compounds structure and their anti-tumor activ-
ity. Based on the molecular weight of three quercetin deriva-
tive compounds in one of these papers [quercetin (302.24) 
> IS (316.2623) > I3G (492.39)], this hypothesis is that 
there might be an inverse relationship between the in vitro 
anti-tumor activity of this compounds and their different 
molecular weight and polarity. Having considered that 
quercetin, IS, I3G, Q3’S and Q3G do not show the cyto-
toxicity activities against the normal mammary epithelial 
cells, these metabolites have likely a proper selectivity on 
the tested tumor cells (Wu et al. 2018a, b).
Combinatory effects with different compounds
Since just a small percentage of the ingested quercetin will 
get absorbed in the blood, quercetin’s poor bioavailability 
has been well proved by now and, therefore, particular deri-
vatization would be able to impressively promote the intes-
tinal absorption and anticancer effects of quercetin (Zhang 
et al. 2012b). On the other hand, it is needless to say that 
the combination of several chemotherapeutic agents exerts 
the stronger effect, decreases drug toxicity and multidrug 
resistance, delays cancer cells development, and achieves 
much more efficacy compared to one individual drug as 
equal concentrations. By accepting these concepts, Yang 
and Liu have tested the effects of apple extracts, which have 
been demonstrated to have the potency of inhibiting NF-κB 
activation in MCF-7 cells, in combination with a quercetin 
derivative, quercetin 3-β-D-Glucoside, on MCF-7 human 
BC cell proliferation. Their obtained results indicated that 
the mentioned combination strikingly enhanced the in vitro 
anti-proliferative activity against MCF-7 BC cells compared 
with the apple extracts and Q3G alone and possess a strong 
synergistic effect against the proliferation of MCF-7 cells 
(Yang and Liu 2009).
Another study on Rutin, quercetin glycoside, by Iriti et al. 
revealed that despite the poor or absent efficacy of Rutin 
against MCF-7 and MB-MDA-231b BC cell lines, this thera-
peutic product enhances the efficacy of the combined chemo-
therapeutic drugs (cyclophosphamide (CYC) and methotrex-
ate (MTX)) (Iriti et al. 2017). The analyses of the function 
of efflux pumps which are expressed by MDA-MB-231 cells 
(P-gp and BCRP) indicated that Rutin’s different affections 
on poorly expressing efflux pump MCF-7 were ineffective 
while on overexpressing efflux pump MDA-MB-231 cells 
were slightly effective. It has been noted that quercetin and 
Rutin are the most sever P-gp inhibitors, both of them could 
remarkably diminish the MDR to Paclitaxel and decrease the 
P-gp protein’s expression rate (Mohana et al. 2016). On the 
other hand, the existence of a –OH group at 4′ position of the 
B-ring and a double bond between positions 2 and 3 of the 
C-ring are associated with great inhibitory activity against 
BCRP (Fig. 5). Overall, Rutin is a non-selectively counter-
acting agent for P-gp and BCRP pumps that may enhance 
the sensitivity to conventional anticancer drugs CYC and 
MTX. A considerable note obtained from their assay was 
that following Rutin’s addition, the same effects have been 
observed in cancer cells by half-dosage administration of 
CYC and MTX in comparison with their therapeutic dose. In 
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conclusion, they reported that the mentioned mechanisms of 
Rutin contribute to MDR reversal in human BC cells and to 
the impairment of cancer cell machinery which is involved 
in drug resistance development (Iriti et al. 2017).
Further detailed investigations on the synthesis of 23 
novel series of methylated quercetin derivatives for ana-
lyzing the association of different side-chain positions and 
their anti-MDR activity revealed similar conclusions about 
the poor chemosensitizing activity of quercetin and Rutin 
and their non-specific efficacy on the ABC transporters. 
Achieved data from the mentioned literature stated the prom-
ising P-gp- and BCRP-mediated MDR reversal activities of 
novel synthetic quercetin derivatives with no inherent cyto-
toxicity to normal mouse fibroblast cell lines. Two important 
structural features which specify the P-gp modulating activ-
ity of quercetin derivatives include methoxy substituents 
numbers on the terminal phenyl ring (fewer methoxy groups 
would exhibit stronger P-gp modulating activity) and linkers 
type at O-3 side chain (a methylene linker at this position 
but not carbonyl linker which can elevate P-gp modulat-
ing activity) but on the other hand carbohydrate side-chain 
methylation exhibited no effect on P-gp-, MRP1- and BCRP-
modulating activities. Their results suggest that the highest 
P-gp modulating activity is displayed by the compound with 
a 3-methoxybenzoyloxyethyl at O-3 (compound 17; Fig. 5), 
promising BCRP-modulating activity is observed by 3, 7, 
30, 40-tetra-O-methylated quercetin or compound with a 3, 
4, 5-trimethoxyphenylacryloyloxyethyl at O-3 or compound 
containing a monomethoxy substituted phenyl linked by an 
ethyleneoxycarbonyl group (compound 9, 14 and 17, respec-
tively; Fig. 5). Interestingly, the last mentioned compound 
was declared to have dual-modulator activities against P-gp 
and BCRP and exhibited the most P-gp-modulating effect; 
thus, due to its equipotent activities, it might be a suitable 
MDR reversal compound. Since any MRP1-modulating 
activity had been obtained from the quercetin derivatives 
at 1.0 mM/mL, the result is that these quercetin derivatives 
have less specificity for MRP1 transporter as compared to 
the P-gp and BCRP transporters and they would be useful, 
safe and effective modulators of drug resistance mediated 
by P-gp or BCRP in cancer cells (Yuan et al. 2012) (Fig. 5).
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Conclusion
In this paper, we discussed existing evidence of quercetin’s 
effects on BC cells proliferation, apoptosis induction, cell 
cycle arrest, metastasis reduction, oxidative stress develop-
ment, and estrogen receptors modulation, as well as drug 
resistance reduction in in vivo and in vitro (Tables 1, 2).
Regarding the fact that there is no decisive evidence 
showing the precise effects of quercetin and mechanisms 
of its activities, more information, and further studies 
are required to clarify the bioavailability and efficacy of 
quercetin and conversions of quercetin to its metabolites 
to pharmacological application in the treatment of diseases 
with immune-pathophysiology such as BC. Acquisition of 
this safe flavonoid compound, with no reported toxicity, 
and its derivatives as potential anticancer agents in the field 
of pharmaceuticals are limited because of its low intrinsic 
activity, poor aqueous solubility, high metabolic rate, poor 
oral bioavailability and absorption, and rapid body clear-
ance. To increase the solubility, bioavailability, circulation 
time, and target specificity of quercetin inside human body, 
numerous scientific efforts on the use of biodegradable and 
biocompatible carriers as delivery systems have been sig-
nificantly noticed, including delivery systems which are 
based on liposomes, PLGA, PLA, chitosan and silica and 
although various studies have been attracted to this subject, 
Table 2  Characteristics of in vivo studies about the anticancer effects of quercetin
References Type of treatment Treatment dose Target Effects observed
Li et al. (2018a, b) Quercetin – BALB/c nu-nu mice Reducing metastasis potenti-
ality and tumorigenesis by 
effecting AKT/PI3K/mTOR 
Signaling pathway
Tao et al. (2015) Quercetin – Nude mouse orthotopic 
xenograft
Significantly enhancement of 
miR-146a expression after 
treatment with quercetin for 
8 weeks
Reduced tumor volume
Rivera et al. (2016) Quercetin 15 mg/kg Female SCID mice Decreasing tumor growth 
until 70%
Zhao et al. (2016) Comparison of quercetin 
with Tamoxifen and 
Tacrolimus
Quercetin 34 mg/kg
Tamoxifen 5.6 mg/kg
Tacrolimus 3 mg/kg
Female BALB/c node mice Decreasing tumor growth
Promoting tumor necrosis
Decreasing serum VEGF 
level
Down regulating VEGF, 
VEGFR and NFATc3 gene 
and protein expression
Suppressing calcineurin/
NFAT pathway
Sánchez-González et al. 
(2017)
Quercetin co-administration 
with cisplatin
Quercetin 30 mg/kg
cisplatin 7 m/kg
EMT6 tumor-bearing mice Reducing the oxidative dam-
age of renal tissue
Decreasing serum BUN and 
creatinine levels
Increasing the GGT and AP 
activity
Inhibiting tumor growth
Balakrishnan et al. (2016) Quercetin conjugated with 
gold nanoparticle
Quercetin 30 mg/kg
AuNP-Qu-5 30 mg/kg
Female Sprague-Dawley 
rats
Increasing body weight of rat
Suppressing tumor growth
Restoring epithelial mam-
mary tissue formation near 
to normal
Jia et al. (2018) Quercetin Quercetin 50 mg/kg Female BALB/c node mice Inhibiting tumor growth
Suppressing PKM2 and pAkt
Increasing Beclin-1 
autophagy marker
Tabaczar et al. (2015) Comparison between 
quercetin and proline
Quercetin 10 mg/kg
Proline 10 mg/kg
female Sprague-Dawley rats Suppressing tumor growth
Inducing apoptosis tumor cell
Restoring GSH pool
Decreasing lipid peroxidase
Reduction in total SOD and 
CuZnSOD activity
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but the future perspective of research should exert optimi-
zation studies to elevate their specificity and efficacy for 
efficient clinical usage.
Moreover, in line with the mentioned information in 
“Drug resistance”, it is also worthwhile to design and man-
age future clinical trials regarding the synergistic effect of 
quercetin in breast cancer’s treatment and prevention.
In summary, the authors hope that this review article pro-
vides a better knowledge of quercetin’s molecular basis of 
action and also elevates the number of dietary preclinical 
and clinical studies with regard to quercetin and other herbal 
substances to assess safety and efficiency of BC’s pharma-
cotherapy. We are of the opinion that available evidence in 
this paper detailed by the actual state of knowledge would 
have a supportive role in finding other junctions between 
active herbal agents like quercetin and other flavonoids with 
different irritating cancers.
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